Episode 54
Biotech Hangout
00:00
The No-Patient Left Behind Initiative Is a Capital Standard
Nimbus and Takeda published the data behind the $4 billion tick-2 deal that was announced recently. Mike, do you want to cover the data? And I would also love for Josh to comment. There's been a wealth of good psoriasis and immunology data recently.
Transcript
Play full episode
